New AI Blood Test Could Become Game Changer for Bowel Cancer Diagnosis

Colorectal cancer (CRC), also referred to as bowel cancer, is the world's third most common cancer and the fourth leading cause of death. It is responsible for approximately 1.4 million new cases and 700,000 deaths every year. In Europe, bowel cancer is the second most prevalent cancer, with 450,000 cases annually. Developed countries have seen an increase in incidence of CRC, and the figures remain high. Early detection of CRC has always been crucial in saving lives. Now, the introduction of a fast, affordable, and scalable test for the early detection of bowel cancer could revolutionize the approach to the diagnosis and screening of this disease.

CanSense Ltd. (Swansea, UK) is harnessing artificial intelligence-based modeling (AI) to create a rapid, affordable, and versatile test that can detect bowel cancer in its early stages, save lives and reduce distress. The test could help dramatically reduce the mortality rate of CRC via early stage diagnosis. It also has the potential to reduce the need for unnecessary invasive colonoscopies and the associated financial burden on healthcare providers.

Negative colonoscopy procedures are associated with considerable economic costs, estimated to be a minimum of USD 4.2 billion worldwide. The blood test can serve as a tool to aid healthcare professionals in determining the necessity of further colonoscopy examinations. From the viewpoint of an anxious symptomatic patient, this approach to CRC triage offers significant advantages. The test can yield quick and accurate results, identifying patients requiring immediate and priority treatment. For those given a negative diagnosis, it effectively eliminates the need for colonoscopy procedures and quickly reduces their anxiety.

Related Links:
CanSense Ltd. 

Visit expo >

Gold Member

TORCH Panel Rapid Test

Rapid TORCH Panel Test

Antipsychotic TDM AssaysSaladax Antipsychotic Assays

New

Automated Nucleic Acid Extractor

eLab

New

ELISA System

ABSOL HS DUO